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2013 is a remarkable year in cardiovascular medicine from a
historical point of view. It can be considered a crown year for
non-invasive clinical cardiovascular imaging as we can look
back on 60 years of echocardiography, 40 years of nuclear
cardiology, 30 years of cardiovascular magnetic resonance
imaging, and 30 years of cardiac computed tomography. In
previous Editor’s Comments, 60 years of echocardiography
and 40 years of nuclear cardiology were described (Parts I and
II) [1, 2]. In this Editor’s Comment (Part III) we will briefly
look back to the roots of cardiovascular magnetic resonance
imaging and its main achievements.
Cardiovascular magnetic resonance 30 years
The year 1983 was a major breakthrough for cardiovascular
nuclear magnetic resonance (NMR). For the first time, var-
ious research groups around the world addressed the huge
clinical potential of NMR in cardiovascular disease [3–7].
At that time, Burdine and Murphy (Texas Heart Institute,
USA) stated that ‘magnetic resonance cardiac imaging is an
exciting new diagnostic modality in which acceptance as a
routine diagnostic tool depends on the results of extensive
clinical trials’ [7]. In order to eliminate the word ‘nuclear’,
with its unpopular public connotation, the name was changed
from NMR to MR imaging or MRI. Later on, cardiovascular
MRI changed into cardiovascular magnetic resonance (CMR).
Over the past 30 years, there have been major technical de-
velopments in CMR which have resulted in improved image
quality allowing the accurate diagnosis and prognosis in pa-
tients with a wide spectrum of cardiovascular diseases such as
coronary artery disease, cardiomyopathies, myocarditis, val-
vular heart disease, and congenital heart disease.
In 1984, the first CMR machine was installed in the
Netherlands (Leiden). In the same year, first moving (cine)
images of the heart by CMR were reported permitting the
visualisation of wall motion abnormities [8]. CMR enabled
the calculation of left ventricular volumes and ejection frac-
tion [9], which turned out be accurate, reliable and repro-
ducible [10]. In 1988, the Leiden group was one of the first
to apply contrast-enhanced imaging using gadolinium-
DTPA in patients following acute myocardial infarction
[11]. The signal intensity ratio of infarcted versus normal
myocardium was significantly greater after the administra-
tion of gadolinium DTPA improving the detection and
localisation of infarct zones by CMR. From that moment
on, myocardial tissue characterisation by virtue of contrast
enhancement has obtained a fixed niche in CMR imaging
[12–16]. In a landmark study using gadolinium-enhanced
CMR in 50 patients with ventricular dysfunction, Kim et al.
(Chicago, USA) showed that reversible myocardial dysfunc-
tion could be identified by contrast-enhanced CMR before
coronary revascularisation [13]. The group directed by
Sechtem (Stuttgart, Germany) showed that localised con-
trast enhancement was a frequent finding in the clinical
setting of suspected myocarditis associated with active in-
flammation defined by histopathology [14]. Using contrast-
enhanced CMR, the Amsterdam VUmc group directed by
Van Rossum showed the presence of localised crypts in the
inferoseptal left ventricular wall in patients with subclinical
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hypertrophic cardiomyopathy [15]. A recent study in pa-
tients with newly diagnosed non-ischaemic cardiomyopathy
showed that contrast-enhanced-positive patients had a worse
prognosis than patients without signs of contrast enhance-
ment [16].
In the late 1980s CMRmyocardial tagging was introduced,
being a new alternative method for non-invasive assessment
of myocardial motion. In addition to simple translation and
rotation, complex motions such as cardiac twist and left ven-
tricular torsion could be demonstrated [17, 18].
In the 1990s, CMR underwent further developments. In
1990, myocardial perfusion imaging by first-pass contrast-
enhanced CMR was introduced based on the transit of
gadolinium-DTPA through the cardiac chambers and myo-
cardium [19]. After induction of vasodilation by either
adenosine or dipyridamole, first-pass perfusion CMR imag-
ing could be performed during intravenous bolus injection
of a gadolinium-based contrast agent in order to detect
perfusion defects in the ischaemic area [20]. In 1991, Man-
ning’s group (Boston, USA) was one of the first to show the
potential of CMR imaging of the coronary arteries using
breath-hold imaging techniques [21]. From that time on,
coronary MR angiography allowed the detection of coro-
nary artery stenosis [22]. In addition, it became possible to
evaluate the functional status of coronary artery bypasses
using high-resolution magnetic resonance angiography [23].
In 1992, Pennell’s group (London, UK) reported the first use
of left ventricular wall motion analyses during dobutamine
stress CMR in 25 patients with exertional chest pain [24].
Dobutamine stress CMR was compared with thallium-201
single photon emission tomography (SPECT) showing a
90 % agreement between SPECT and dobutamine stress
CMR for identifying myocardial ischaemia. In 1994, it
was shown that dobutamine CMR clearly identified wall
motion abnormalities by quantitative analysis using a mod-
ification of the centreline method, developed by Reiber’s
group (Leiden, NL) [25]. In one of the first prognostic
dobutamine CMR studies, Kuijpers and Van Dijkman (The
Hague, NL) reported a positive and negative predictive
value of 95 % and 93 %, respectively, for identifying major
adverse cardiac events by dobutamine CMR imaging.
Apart from its value in coronary artery disease, CMR has
established a fixed niche in patients with structural and con-
genital heart disease [26–29]. Using velocity mapping tech-
niques it was shown that CMR was well suited to detect
changes in aortic stiffness bymeasuring distensibility and pulse
wave velocity, for example in the Marfan syndrome [29].
From 2000 on, newer CMR techniques involving real-
time imaging and 3-D data acquisitions with parallel imag-
ing have increased efficiency in data acquisition. The in-
creased availability of 3 Tesla MRI scanners provided an
enhanced signal which increased the applications in general
clinical practice [30–34]. Developments in contrast agents
and molecular imaging agents further extended the potential
applications of CMR. In recent years, CMR allowed the
characterisation of plaque composition, i.e. the discrimina-
tion of lipid core, fibrosis, calcification, and intra-plaque
haemorrhage deposits [35]. Identification of subclinical ath-
erosclerosis and early treatment initiation has the potential
to surpass conventional risk factor assessment and manage-
ment in terms of overall impact on cardiovascular morbidity
and mortality.
In summary, over the past 30 years CMR has evolved into
an extremely useful diagnostic modality in cardiovascular
disease. It offers new insights into cardiac pathophysiology
and aids in the diagnosis of a wide spectrum of cardiovascular
diseases. Although a single CMR exam may provide a com-
prehensive assessment for aetiologies of various cardiovascu-
lar diseases, hybrid imaging may become more informative
and cost-effective in the long run [36–39]. With expanding
expertise and recognition of its diagnostic and prognostic
power, CMR will grow in importance in the armamentarium
of the cardiac imager for years to come.
N.B. This Editors comment highlights only a selected
number of achievements in CMR. For a more detailed
description of the achievements by CMR the reader is re-
ferred to more in-depth publications [40–43].
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